DOSAGE INDEX / SINGLE
Ipamorelin
Research, reported schedules and supply planning.
Examine ipamorelin human hormone studies, the postoperative trial, animal findings and FDA safety concerns without overstating clinical benefits.
Source: PeptideDosages.com. Independently written summaries of reported protocols, not validated treatment recommendations. Reviewed for transcription on September 21, 2026.
Research Protocol & Dosage
Source-reported examples · not treatment recommendations
Reported example 1
- Amount
- 100–250 micrograms per day
- Frequency
- Once daily
- Cycle / observation period
- 8–12 weeks, potentially 16; source describes a 2–4 week pause
- Route / research model
- Subcutaneous
The 10 mg vial page lists a higher upper amount.
Reported example 2
- Amount
- 100–300 micrograms per day
- Frequency
- Once daily
- Cycle / observation period
- 8–12 weeks, potentially 16; source describes a 2–4 week pause
- Route / research model
- Subcutaneous
The 5 mg vial page instead lists an upper amount of 250 micrograms.
Titration & progression
A dose range is not a titration schedule. No independently verified stepwise escalation has been established for this source-reported regimen.
Supply & Planning
Compare vial strengths here. A different vial size changes the available material, not the biological dose.
Diluent & formulation
Diluent compatibility is formulation-specific. A verified manufacturer instruction is still needed before bacteriostatic water or another diluent can be listed as suitable for this research material.
Vial comparison
No single complete schedule is resolved for this entry. Enter a documented total to compare strengths; the calculator does not select a regimen.
| Vial strength | Vials needed |
|---|---|
| 5 mg | Enter a total |
| 10 mg | Enter a total |
Enter a positive material total.
Material minimum only: round total material ÷ vial content up to a whole vial. Actual supply may be higher because of single-use packaging, discard dates, dead space or losses. No validated multi-use storage period is assumed.
Reported Research Results
Selected observations from the cited research. Each finding retains its study population, formulation and limitations.
- A 1999 study used five intravenous infusion levels with eight healthy male participants at each level. It measured ipamorelin concentrations and GH responses. The estimated terminal half-life was about two hours, and GH release peaked around 0.67 hours after administration. The study modeled drug exposure and hormone response rather than long-term clinical benefit. [1]
- A phase 2, randomized, double-blind trial enrolled 117 adults undergoing bowel resection; 114 were included in the safety and modified intention-to-treat populations. Intravenous ipamorelin was compared with placebo during postoperative recovery. The key endpoint was time from the first dose to tolerating a standardized solid meal. Median times were 25.3 and 32.6 hours, respectively, with P=.15. Key and secondary efficacy analyses did not show significant differences. [2]
- FDA's October 2024 assessment also described two fatal serious adverse events in ipamorelin-treated surgical patients. It explicitly stated that whether the deaths were related to ipamorelin was unclear. The assessment raised concerns about other adverse findings and missing safety data for the proposed subcutaneous route. [3]
- A mouse study compared ipamorelin with GH in animals with different GH status. Ipamorelin increased relative fat-pad weights in the reported groups, and GH secretagogue treatment increased relative body fat in GH-intact mice. Increased food intake was also observed with secretagogue treatment. [4]
Sourcing & Vendor Information
No compound-specific affiliate destination is listed here yet. Browse the Vendors Index for the available supplier records and disclosed relationships.
Sources & Further Reading
Medical publications and supporting literature from the corresponding protocol bibliographies, combined across vial strengths. Supplier and commercial catalog references are excluded. Duplicate destinations appear once. Inclusion does not mean that a paper validates the reported dose, or that an ingredient study tests the finished blend.
Bibliography checked September 22, 2026: 24 entries mapped from 2 source pages. Medical and supporting references are retained below; supplier entries are excluded.
- Original human PK/PD study
- Original postoperative trial
- FDA's detailed assessment
- Original adiposity study
- Translational Andrology and Urology (PMC)Further reading · Listed in reference bibliography.
- European Journal of Endocrinology (PubMed)Further reading · Listed in reference bibliography.
- European Journal of AnatomyFurther reading · Listed in reference bibliography.
- Johns Hopkins Arthritis CenterGeneral guidance · Listed in reference bibliography.
- NCBI BookshelfFurther reading · Listed in reference bibliography.
- Pharmacologic Considerations (PMC)Further reading · Listed in reference bibliography.
- NIBSC (National Institute for Biological Standards)Further reading · Listed in reference bibliography.
Reported schedule reference: PeptideDosages.com. Research findings are summarized independently from the listed sources.